High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients
While treatment of localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is based on surgery, brachytherapy, which delivers a high dose of radiation to tumor tissue while sparing healthy tissue, is an alternative. Since the withdrawal of iridium wires from the market, brac...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-08, Vol.16 (15), p.2742 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 15 |
| container_start_page | 2742 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Monge-Cadet, Jeanne Vairel, Benjamin Morisseau, Mathilde Moyal, Elizabeth Ducassou, Anne Chira, Ciprian Pagès, Cécile Sibaud, Vincent Brun, Thomas Modesto, Anouchka |
| description | While treatment of localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is based on surgery, brachytherapy, which delivers a high dose of radiation to tumor tissue while sparing healthy tissue, is an alternative. Since the withdrawal of iridium wires from the market, brachytherapy has mainly been performed with high-dose-rate iridium-192 (HDR). This study evaluated the efficacy of HDR brachytherapy in terms of local control, survival, toxicity, and quality of life in patients with facial periorificial cutaneous SCC or BCC treated in our center between 2015 and 2021. Sixty-seven patients were treated for SCC (
= 49) or BCC (
= 18), on the nose (
= 29), lip (
= 28), eyelid (
= 7), or ear (
= 3). The majority had Tis or T1 tumors (73.1%). After a median follow-up of 28 months, 8 patients had a local recurrence. The local control rate at 3 years was 87.05% (95% CI 74.6-93.7). All patients developed grade 1-2 acute radio-mucositis or radiodermatitis and one experienced reversible grade 3 acute radio-mucositis. Of the 27 patients who completed the quality-of-life questionnaire, 77.8% recommended the treatment. This study confirms that HDR brachytherapy for facial cutaneous carcinomas provides good local control, good tolerance, and satisfactory functional outcome. |
| doi_str_mv | 10.3390/cancers16152742 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04854270v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A804513687</galeid><sourcerecordid>A804513687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-8dbc20a46498ce23f2189ca8ce1d1db481defb3e77a61ea5bc91f7985e3f078f3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpmRuyxAWkpvVXYofbslAWKRJfy9lynHHXJRsvtoPYC78dhy0FKuyDx6Pnfe0ZTVE8JvicsQZfGD0aCJHUpKKC03vFMcWClnXd8Pt_xUfFaYzXOC_GiKjFw-KINYQyLshx8WPlrjblKx-h_KgToJdBm80-bSDo3R5ZH9A6gE5bGBPyFl1q4_SAPn1xI1oenn-BWm9ybunHFPxwhtb-uzMu7c-QHnv0YdJDvszi1llAWVgL9F4nly3jo-KB1UOE05vzpPh8-Xq9XJXtuzdvl4u2NKwiqZR9ZyjWvOaNNECZpUQ2RueY9KTvuCQ92I6BELomoKvONMSKRlbALBbSspPi-cF3owe1C26rw1557dRq0ao5h7msOBX4G8nsswO7C_7rBDGprYsGhkGP4KeoGM7dk1xIkdGnd9BrP4UxVzJTWEoqBPtDXekBlButT7nLs6laSMwrwupfXuf_ofLuYeuMH8G6nP9HcHEQmOBjDGBvCyNYzQOi7gxIVjy5-e7UbaG_5X-PA_sJhbO0KA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090882773</pqid></control><display><type>article</type><title>High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Monge-Cadet, Jeanne ; Vairel, Benjamin ; Morisseau, Mathilde ; Moyal, Elizabeth ; Ducassou, Anne ; Chira, Ciprian ; Pagès, Cécile ; Sibaud, Vincent ; Brun, Thomas ; Modesto, Anouchka</creator><creatorcontrib>Monge-Cadet, Jeanne ; Vairel, Benjamin ; Morisseau, Mathilde ; Moyal, Elizabeth ; Ducassou, Anne ; Chira, Ciprian ; Pagès, Cécile ; Sibaud, Vincent ; Brun, Thomas ; Modesto, Anouchka</creatorcontrib><description>While treatment of localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is based on surgery, brachytherapy, which delivers a high dose of radiation to tumor tissue while sparing healthy tissue, is an alternative. Since the withdrawal of iridium wires from the market, brachytherapy has mainly been performed with high-dose-rate iridium-192 (HDR). This study evaluated the efficacy of HDR brachytherapy in terms of local control, survival, toxicity, and quality of life in patients with facial periorificial cutaneous SCC or BCC treated in our center between 2015 and 2021. Sixty-seven patients were treated for SCC (
= 49) or BCC (
= 18), on the nose (
= 29), lip (
= 28), eyelid (
= 7), or ear (
= 3). The majority had Tis or T1 tumors (73.1%). After a median follow-up of 28 months, 8 patients had a local recurrence. The local control rate at 3 years was 87.05% (95% CI 74.6-93.7). All patients developed grade 1-2 acute radio-mucositis or radiodermatitis and one experienced reversible grade 3 acute radio-mucositis. Of the 27 patients who completed the quality-of-life questionnaire, 77.8% recommended the treatment. This study confirms that HDR brachytherapy for facial cutaneous carcinomas provides good local control, good tolerance, and satisfactory functional outcome.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16152742</identifier><identifier>PMID: 39123471</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Basal cell carcinoma ; Biopsy ; Brachytherapy ; Cancer ; Cancer therapies ; Care and treatment ; Dermatologic agents ; Dermatology ; Dissection ; Dosage and administration ; Dosimetry ; Eyelid ; Formulae, receipts, prescriptions ; Life Sciences ; Lymphatic system ; Mucositis ; Neck ; Patients ; Quality of life ; Questionnaires ; Radiation therapy ; Radioisotope brachytherapy ; Skin ; Squamous cell carcinoma ; Toxicity ; Tumors</subject><ispartof>Cancers, 2024-08, Vol.16 (15), p.2742</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c351t-8dbc20a46498ce23f2189ca8ce1d1db481defb3e77a61ea5bc91f7985e3f078f3</cites><orcidid>0009-0006-8575-4443 ; 0000-0003-2133-6454 ; 0000-0003-2585-6633</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39123471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04854270$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Monge-Cadet, Jeanne</creatorcontrib><creatorcontrib>Vairel, Benjamin</creatorcontrib><creatorcontrib>Morisseau, Mathilde</creatorcontrib><creatorcontrib>Moyal, Elizabeth</creatorcontrib><creatorcontrib>Ducassou, Anne</creatorcontrib><creatorcontrib>Chira, Ciprian</creatorcontrib><creatorcontrib>Pagès, Cécile</creatorcontrib><creatorcontrib>Sibaud, Vincent</creatorcontrib><creatorcontrib>Brun, Thomas</creatorcontrib><creatorcontrib>Modesto, Anouchka</creatorcontrib><title>High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>While treatment of localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is based on surgery, brachytherapy, which delivers a high dose of radiation to tumor tissue while sparing healthy tissue, is an alternative. Since the withdrawal of iridium wires from the market, brachytherapy has mainly been performed with high-dose-rate iridium-192 (HDR). This study evaluated the efficacy of HDR brachytherapy in terms of local control, survival, toxicity, and quality of life in patients with facial periorificial cutaneous SCC or BCC treated in our center between 2015 and 2021. Sixty-seven patients were treated for SCC (
= 49) or BCC (
= 18), on the nose (
= 29), lip (
= 28), eyelid (
= 7), or ear (
= 3). The majority had Tis or T1 tumors (73.1%). After a median follow-up of 28 months, 8 patients had a local recurrence. The local control rate at 3 years was 87.05% (95% CI 74.6-93.7). All patients developed grade 1-2 acute radio-mucositis or radiodermatitis and one experienced reversible grade 3 acute radio-mucositis. Of the 27 patients who completed the quality-of-life questionnaire, 77.8% recommended the treatment. This study confirms that HDR brachytherapy for facial cutaneous carcinomas provides good local control, good tolerance, and satisfactory functional outcome.</description><subject>Basal cell carcinoma</subject><subject>Biopsy</subject><subject>Brachytherapy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Dermatologic agents</subject><subject>Dermatology</subject><subject>Dissection</subject><subject>Dosage and administration</subject><subject>Dosimetry</subject><subject>Eyelid</subject><subject>Formulae, receipts, prescriptions</subject><subject>Life Sciences</subject><subject>Lymphatic system</subject><subject>Mucositis</subject><subject>Neck</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Questionnaires</subject><subject>Radiation therapy</subject><subject>Radioisotope brachytherapy</subject><subject>Skin</subject><subject>Squamous cell carcinoma</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhiMEolXpmRuyxAWkpvVXYofbslAWKRJfy9lynHHXJRsvtoPYC78dhy0FKuyDx6Pnfe0ZTVE8JvicsQZfGD0aCJHUpKKC03vFMcWClnXd8Pt_xUfFaYzXOC_GiKjFw-KINYQyLshx8WPlrjblKx-h_KgToJdBm80-bSDo3R5ZH9A6gE5bGBPyFl1q4_SAPn1xI1oenn-BWm9ybunHFPxwhtb-uzMu7c-QHnv0YdJDvszi1llAWVgL9F4nly3jo-KB1UOE05vzpPh8-Xq9XJXtuzdvl4u2NKwiqZR9ZyjWvOaNNECZpUQ2RueY9KTvuCQ92I6BELomoKvONMSKRlbALBbSspPi-cF3owe1C26rw1557dRq0ao5h7msOBX4G8nsswO7C_7rBDGprYsGhkGP4KeoGM7dk1xIkdGnd9BrP4UxVzJTWEoqBPtDXekBlButT7nLs6laSMwrwupfXuf_ofLuYeuMH8G6nP9HcHEQmOBjDGBvCyNYzQOi7gxIVjy5-e7UbaG_5X-PA_sJhbO0KA</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Monge-Cadet, Jeanne</creator><creator>Vairel, Benjamin</creator><creator>Morisseau, Mathilde</creator><creator>Moyal, Elizabeth</creator><creator>Ducassou, Anne</creator><creator>Chira, Ciprian</creator><creator>Pagès, Cécile</creator><creator>Sibaud, Vincent</creator><creator>Brun, Thomas</creator><creator>Modesto, Anouchka</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0009-0006-8575-4443</orcidid><orcidid>https://orcid.org/0000-0003-2133-6454</orcidid><orcidid>https://orcid.org/0000-0003-2585-6633</orcidid></search><sort><creationdate>20240801</creationdate><title>High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients</title><author>Monge-Cadet, Jeanne ; Vairel, Benjamin ; Morisseau, Mathilde ; Moyal, Elizabeth ; Ducassou, Anne ; Chira, Ciprian ; Pagès, Cécile ; Sibaud, Vincent ; Brun, Thomas ; Modesto, Anouchka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-8dbc20a46498ce23f2189ca8ce1d1db481defb3e77a61ea5bc91f7985e3f078f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Basal cell carcinoma</topic><topic>Biopsy</topic><topic>Brachytherapy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Dermatologic agents</topic><topic>Dermatology</topic><topic>Dissection</topic><topic>Dosage and administration</topic><topic>Dosimetry</topic><topic>Eyelid</topic><topic>Formulae, receipts, prescriptions</topic><topic>Life Sciences</topic><topic>Lymphatic system</topic><topic>Mucositis</topic><topic>Neck</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Questionnaires</topic><topic>Radiation therapy</topic><topic>Radioisotope brachytherapy</topic><topic>Skin</topic><topic>Squamous cell carcinoma</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Monge-Cadet, Jeanne</creatorcontrib><creatorcontrib>Vairel, Benjamin</creatorcontrib><creatorcontrib>Morisseau, Mathilde</creatorcontrib><creatorcontrib>Moyal, Elizabeth</creatorcontrib><creatorcontrib>Ducassou, Anne</creatorcontrib><creatorcontrib>Chira, Ciprian</creatorcontrib><creatorcontrib>Pagès, Cécile</creatorcontrib><creatorcontrib>Sibaud, Vincent</creatorcontrib><creatorcontrib>Brun, Thomas</creatorcontrib><creatorcontrib>Modesto, Anouchka</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Monge-Cadet, Jeanne</au><au>Vairel, Benjamin</au><au>Morisseau, Mathilde</au><au>Moyal, Elizabeth</au><au>Ducassou, Anne</au><au>Chira, Ciprian</au><au>Pagès, Cécile</au><au>Sibaud, Vincent</au><au>Brun, Thomas</au><au>Modesto, Anouchka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>16</volume><issue>15</issue><spage>2742</spage><pages>2742-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>While treatment of localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is based on surgery, brachytherapy, which delivers a high dose of radiation to tumor tissue while sparing healthy tissue, is an alternative. Since the withdrawal of iridium wires from the market, brachytherapy has mainly been performed with high-dose-rate iridium-192 (HDR). This study evaluated the efficacy of HDR brachytherapy in terms of local control, survival, toxicity, and quality of life in patients with facial periorificial cutaneous SCC or BCC treated in our center between 2015 and 2021. Sixty-seven patients were treated for SCC (
= 49) or BCC (
= 18), on the nose (
= 29), lip (
= 28), eyelid (
= 7), or ear (
= 3). The majority had Tis or T1 tumors (73.1%). After a median follow-up of 28 months, 8 patients had a local recurrence. The local control rate at 3 years was 87.05% (95% CI 74.6-93.7). All patients developed grade 1-2 acute radio-mucositis or radiodermatitis and one experienced reversible grade 3 acute radio-mucositis. Of the 27 patients who completed the quality-of-life questionnaire, 77.8% recommended the treatment. This study confirms that HDR brachytherapy for facial cutaneous carcinomas provides good local control, good tolerance, and satisfactory functional outcome.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39123471</pmid><doi>10.3390/cancers16152742</doi><orcidid>https://orcid.org/0009-0006-8575-4443</orcidid><orcidid>https://orcid.org/0000-0003-2133-6454</orcidid><orcidid>https://orcid.org/0000-0003-2585-6633</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-08, Vol.16 (15), p.2742 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04854270v1 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Basal cell carcinoma Biopsy Brachytherapy Cancer Cancer therapies Care and treatment Dermatologic agents Dermatology Dissection Dosage and administration Dosimetry Eyelid Formulae, receipts, prescriptions Life Sciences Lymphatic system Mucositis Neck Patients Quality of life Questionnaires Radiation therapy Radioisotope brachytherapy Skin Squamous cell carcinoma Toxicity Tumors |
| title | High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A24%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-Dose-Rate%20Brachytherapy%20for%20Treatment%20of%20Facial%20Skin%20Cancers:%20Local%20Control,%20Toxicity,%20and%20Quality%20of%20Life%20in%2067%20Patients&rft.jtitle=Cancers&rft.au=Monge-Cadet,%20Jeanne&rft.date=2024-08-01&rft.volume=16&rft.issue=15&rft.spage=2742&rft.pages=2742-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16152742&rft_dat=%3Cgale_hal_p%3EA804513687%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3090882773&rft_id=info:pmid/39123471&rft_galeid=A804513687&rfr_iscdi=true |